Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + allogeneic NK cell immunotherapy
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic natural killer (NK) cell immunotherapy is a cellular biologic therapy developed by Fuda Cancer Hospital in Guangzhou, China. The therapy involves the ex vivo expansion of allogeneic NK cells, which are then administered intravenously to target and destroy cancer cells through natural killer cell-mediated cytotoxicity. In clinical settings, particularly for advanced non-small cell lung cancer (NSCLC) and recurrent solid tumors, it is evaluated in combination with the PD-1 inhibitor pembrolizumab. This combination approach aims to enhance the anti-tumor immune response by combining the direct cytotoxic effects of NK cells with the checkpoint inhibition provided by pembrolizumab. Clinical studies have demonstrated that this combination can yield improved survival benefits in patients with previously treated PD-L1 positive advanced NSCLC compared to pembrolizumab monotherapy.
- Other names
- NK immunotherapyHANKhighly activated NK cellsallogeneic natural killer cell immunotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + allogeneic NK cell immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + allogeneic NK cell immunotherapy.